NasdaqGS:RAREBiotechs
Does Rising GTX-102 Focus Recast Ultragenyx (RARE) as a Concentrated Angelman Syndrome Risk-Reward Story?
Ultragenyx Pharmaceutical recently highlighted CEO Emil Kakkis’s participation in a fireside chat at Goldman Sachs’ 47th Annual Global Healthcare Conference and drew increased attention as one of hedge funds’ most promising mid-cap healthcare names, with analyst commentary emphasizing growing institutional interest in its rare-disease pipeline.
A key focus of this attention is GTX-102 for Angelman syndrome, where analyst assessments and hedge fund interest underscore how expectations around...